Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy.

Turpin BK, Morris VR, Lemen L, Weiss BD, Gelfand MJ.

Health Phys. 2013 Feb;104(2 Suppl 1):S43-6. doi: 10.1097/HP.0b013e318277659a.

PMID:
23287519
2.

Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.

Markelewicz RJ Jr, Lorenzen WA, Shusterman S, Grant FD, Fahey FH, Treves ST.

Clin Nucl Med. 2013 Aug;38(8):604-7. doi: 10.1097/RLU.0b013e31829af3c8.

PMID:
23797228
3.

Task-specific monitoring of nuclear medicine technologists' radiation exposure.

Smart R.

Radiat Prot Dosimetry. 2004;109(3):201-9.

PMID:
15254324
4.

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.

Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J.

J Nucl Med. 2012 Jul;53(7):1155-63. doi: 10.2967/jnumed.111.098624. Epub 2012 Jun 14. Erratum in: J Nucl Med. 2016 Jun;57(6):988.

5.

Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-lipiodol therapy for hepatocellular carcinoma.

Garin E, Laffont S, Rolland Y, Olivie D, Lecloirec J, Herry JY, Boucher E, Raoul JL, Bourguet P.

Nucl Med Commun. 2003 Jun;24(6):671-8.

PMID:
12766603
6.

Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.

Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M, Maris JM.

J Pediatr Hematol Oncol. 2003 Oct;25(10):769-73.

PMID:
14528098
7.

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B.

J Nucl Med. 2001 Nov;42(11):1713-21.

8.

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.

J Clin Oncol. 2007 Mar 20;25(9):1054-60.

PMID:
17369569
9.

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.

Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C, Lanino E, Bertolazzi L, Villavecchia GP, Cabria M, Scopinaro G, Claudiani F, De Bernardi B.

Br J Cancer. 1999 Dec;81(8):1378-84.

10.

Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).

Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK.

Pediatr Blood Cancer. 2016 Mar;63(3):436-42. doi: 10.1002/pbc.25816. Epub 2015 Oct 27.

PMID:
26506090
11.

Measuring and minimizing the radiation dose to nuclear medicine technologists.

Lundberg TM, Gray PJ, Bartlett ML.

J Nucl Med Technol. 2002 Mar;30(1):25-30.

12.

Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.

Mastrangelo S, Tornesello A, Diociaiuti L, Riccardi R, Rufini V, Troncone L.

Q J Nucl Med. 1995 Dec;39(4 Suppl 1):69-71.

PMID:
9002754
13.

Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.

Flower MA, Fielding SL.

Phys Med Biol. 1996 Oct;41(10):1933-40.

PMID:
8912372
14.

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Modak S, Zanzonico P, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N.

J Nucl Med. 2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752. Epub 2016 Jan 7.

15.

Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).

Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK.

Ann N Y Acad Sci. 2006 Aug;1073:465-90.

PMID:
17102115
16.

The treatment of neuroblastoma with [131I]MIBG at diagnosis.

Troncone L, Rufini V, Luzi S, Mastrangelo R, Riccardi R.

Q J Nucl Med. 1995 Dec;39(4 Suppl 1):65-8.

PMID:
9002753
17.

External radiation doses to nuclear medicine technologists from procedures using 99mTc radiopharmaceuticals.

Boutcher S, Haas T.

Can J Radiogr Radiother Nucl Med. 1985 Oct;16(4):161-5.

PMID:
10274037
18.

Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: report of the first two cases.

Clement SC, Kraal KC, van Eck-Smit BL, van den Bos C, Kremer LC, Tytgat GA, van Santen HM.

J Clin Endocrinol Metab. 2014 Jan;99(1):E112-6. doi: 10.1210/jc.2013-3595. Epub 2013 Dec 4.

PMID:
24187404
19.

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.

Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR, De Bernardi B, Haupt R.

Cancer. 2003 Mar 1;97(5):1332-8.

20.

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.

DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK.

J Clin Oncol. 2004 Jun 15;22(12):2452-60.

PMID:
15197208

Supplemental Content

Support Center